Biocompatible dialysis fluids for peritoneal dialysis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Cho, Yeoungjee ^a   Johnson, David W ^a   Craig, Jonathan C ^b,c   Strippoli, Giovanni F M ^b,c,d,e   Badve, Sunil V ^a   Wiggins, Kathryn J ^f  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d UNIVERSITY OF BARI   (Italy)

^e Medical Scientific Office   (Sweden)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; DIALYSIS FLUID; GLUCOSE POLYMER; ICODEXTRIN; LACTIC ACID;

BIOCOMPATIBILITY; HUMAN; HYPERVOLEMIA; INCIDENCE; KIDNEY FUNCTION; MEMBRANE DAMAGE; PERITONEAL DIALYSIS; PERITONITIS; PH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT FAILURE; ULTRAFILTRATION; URINE VOLUME;

EID: 84983688769     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007554.pub2     Document Type: Review

References (112)

1. Bajo MA, Priez-Lozano ML, Albar-Vizcaino P, Del Peso G, Castro MJ, Gonzalez-Mateo G, et al. Low-GDP peritoneal dialysis fluid ('balance') has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid. Nephrology Dialysis Transplantation 2011;26(1):282-91. [MEDLINE: 2057109]
2. Brown F, Johnson DW. A randomized controlled trial to determine whether treatment with at neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients. Peritoneal Dialysis International 2006;26(1):112-3. [MEDLINE: 1653888]
3. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. Journal of the American Society of Nephrology 2012;23(6):1097-107. [MEDLINE: 2244090]
4. Johnson DW, Clarke M, Wilson V, Woods F, Brown FG. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function. BMC Nephrology 2010;11:25. [MEDLINE: 2084337]
5. Woodrow G. A randomized controlled trial to determine whether treatment with at neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients. Peritoneal Dialysis International 2006;26(1):113-4. [MEDLINE: 1654151]
6. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF. Effects on peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Netherlands Journal of Medicine 2001;58:A11. [CENTRAL: CN-0071606]
7. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Peritoneal Dialysis International 2001;21(3): 275-81. [MEDLINE: 1147534]
8. Bredie SJH, Bosch F, Demacker PNM, Stalenhoef AFH, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):203A-4A. [CENTRAL: CN-0055044]
9. Cancarini GC, Faict D, De Vos C, Guiberteau R, Tranaeus A, Minetti L, et al. Clinical evaluation of a peritoneal dialysis solution with 33 mmol/L bicarbonate. Peritoneal Dialysis International 1998;18(6):576-82. [MEDLINE: 993265]
10. Carrasco AM, Rubio MA, Sanchez Tommero JA, Fernandez Giron F, Gonzalez RicoM, del Peso Gilsanz G, et al. Acidosis correction with a new 25 mmol/l bicarbonate/15 mmol/l lactate peritoneal dialysis solution. Peritoneal Dialysis International 2001;21(6):546-53. [MEDLINE: 1178376]
11. Choi HY, Kim DK, Lee TH, Han SH, Lee SC, Lee JE, et al. The clinical impacts of novel peritoneal dialysis fluids (PDFs) with neutral pH and low glucose degradation product (GDP) concentration (Balance®) [abstract no: SP708]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv254. [CENTRAL: CN-0065380]
12. Choi HY, Kim DK, Lee TH, Moon SJ, Han SH, Lee JE, et al. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Peritoneal Dialysis International 2008;28(2):174-82. [MEDLINE: 1833245]
13. Lee HY, Choi HY, Kim JS, Han SH, Lee SC, Lee JE, et al. The clinical usefulness of peritoneal dialysis fluids (PDFs) with neutral pH and low glucose degradation product (GDP) Concentration-Balance® [abstract no: SA-FC138]. Journal of the American Society of Nephrology 2005;16:112A. [CENTRAL: CN-0065380]
14. Cnossen TT, Gladziwa U, van de Kerkhof JJ, Schalkwijk CG, Scheijen J, van Amersfoort J, et al. The influence of bicarbonate/lactate-buffered PD fluids on N-(carboxyethyl)lysine and N-(carboxymethyl)lysine in peritoneal effluent. Peritoneal Dialysis International 2011; 31(2):189-93. [MEDLINE: 2067110]
15. Coles GA, Gokal R, Ogg C, Jani F, O'Donoghue DT, Cancarini GC, et al. A randomized controlled trial of a bicarbonate-and a bicarbonate/lactate-containing dialysis solution in CAPD. Peritoneal Dialysis International 1997;17 (1):48-51. [MEDLINE: 906802]
16. Coles GA, O'Donoghue DJ, Pritchard N, Ogg CS, Jani FM, Gokal R, et al. A controlled trial of two bicarbonatecontaining dialysis fluids for CAPD-final report. Nephrology Dialysis Transplantation 1998;13(12):3165-71. [MEDLINE: 987048]
17. Mackenzie RK, Jones S, Moseley A, Holmes CJ, Argyle R, Williams JD, et al. In vivo exposure to bicarbonate/lactateand bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function. American Journal of Kidney Diseases 2000;35(1):112-21. [MEDLINE: 1062055]
18. Topley N, Mackenzie R, Williams JD, Coles GA, Tranaeus A, Faict D, et al. In vivo exposure to bicarbonate/lactatebuffered pdf (tbl) improves ex vivo pmo function, compared to bicarbonate-(tb) or lactate-buffered pdf (pd4) [abstract]. Nephrology 1997;3(Suppl 1):S408. [CENTRAL: CN-0046187]
19. Williams JD, Holmes CJ, Jones S, Mackenzie R, Coles GA, Faict D, et al. Long-term in vivo exposure to bicarbonate/lactate dialysis fluid improves ex vivo peritoneal macrophage (PMO) TNFa secretion [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):292A. [CENTRAL: CN-0044837]
20. Davies S, Plum J, Heimburger O. Increasing our understanding of the mechanism of action of icodextrin (ICO) [abstract no: F-PO407]. Journal of the American Society of Nephrology 2004;15(Oct):156A. [CENTRAL: CN-0058322]
21. Davies S, Woodrow G, Johansson C, Williams P, Divino J. Icodextrin improves fluid balance in PD patients [abstract no: O52]. Nephrology Dialysis Transplantation 2002;17 (Suppl 1):17. [CENTRAL: CN-0050915]
22. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. Journal of the American Society of Nephrology 2003;14(9):2338-44. [MEDLINE: 1293731]
23. Davies SJ, Woodrow G, Plum J, Heimburger O, Donovan K, Divino J. Icodextrin improves fluid status in PD patients [abstract no: SU-PO798]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts): 632A-3A. [CENTRAL: CN-0044500]
24. di Paolo B, Stingone A, Di Vito R, Stuard S, D'Angelo B, Caravelli L, et al. Cardiovascular and hemodynamic profile related to hypotensive effect long term of icodextrine (ico) in CAPD patients [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):206A. [CENTRAL: CN-0055066]
25. Haag-Weber M, Haug U, Wieslander A, Nabut J, Deppisch R, DIUREST Study Group. Decline of residual renal function (RRF) in peritoneal dialysis (PD) patients (pts) depends on uptake of carbonyl compounds (CC) from the peritoneal cavity: first data of a prospective clinical trial [abstract]. Journal of the American Society of Nephrology 2003;14:476A-7A. [CENTRAL: CN-0075611]
26. Haag-Weber M, Kramer R, Haake R, Islam MS, Prischl F, Haug U, et al. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrology Dialysis Transplantation 2010;25(7):2288-96. [MEDLINE: 2019728]
27. Mackenzie RK, Craig KJ, Lage C, Williams JD, Schaub T, Passlick-Deetjen J, et al. Treatment with low GDP solution (CAPD balance) is associated with an increase in effluent CA125 and a decrease in HA content: data from the multi centre European Balance Trial [abstract no: FP0685]. Journal of the American Society of Nephrology 2002; 13(September, Program & Abstracts):199A. [CENTRAL: CN-0044652]
28. Mackenzie RM, Lage C, Craig KJ, Williams JD, Schaub T, Passlick-Deetjen J, et al. Continuous treatment with low GDP solution (CAPD Balance®) is associated with an increase in effluent CA125 and a decrease in HA content: data from the Multicenter European Balance Trial [abstract]. Peritoneal Dialysis International 2002;22(1):101. [CENTRAL: CN-0044652]
29. Williams JD, Craig KJ, Passlick-Deetjen J, Topley N, Lage C, Pischetsrieder M, et al. Reduced systemic AGE formation with a low GDP solution (CAPD balance): data from the multicentre European Balance Trial [abstract no: FPO683]. Journal of the American Society of Nephrology 2002; 13(September, Program & Abstracts):199A. [CENTRAL: CN-0044837]
30. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney International 2004;66(1):408-18. [MEDLINE: 1520045]
31. Witowski J, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Jorres A, Lage C, et al. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrology Dialysis Transplantation 2004;19(4):917-24. [MEDLINE: 1503135]
32. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney International 2008;73(2):200-6. [MEDLINE: 1791435]
33. Srivastava S, Hildebrand S, Fan SL. Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival. Kidney International 2011;80(9): 986-91. [MEDLINE: 2181417]
34. Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney International 1998;54(5):1731-8. [MEDLINE: 984415]
35. Feriani M, Pablick-Deetjen J, Brown C, Buoncristiani U, Di Paolo N, Gahl G, et al. An open controlled randomized clinical trial with bicarbonate CAPD solutions: interim results [abstract]. Journal of the American Society of Nephrology 1994;5(3):414. [CENTRAL: CN-0055065]
36. Feriani M, Passlick-Deetjen J, Kirchgessner J. Long term safety and efficacy of bicarbonate buffered peritoneal dialysis solutions [abstract]. Nephrology Dialysis Transplantation 1996;11(6):A253. [CENTRAL: CN-0026131]
37. Passlick-Deetjen J, Feriani M. Experiences with bicarbonate solutions in peritoneal dialysis [Erfahrungen mit bikarbonathaltigen peritonealdialyselosungen]. Nierenund Hochdruckkrankheiten 1994;23(Suppl 2):S82-7. [EMBASE: 199501481]
38. Fernandez Perpen A, Sanchez Tomero JA, Bajo MA, Perez Lozano ML, Del Peso G, Albar P, et al. Effects of bicavera (BV) dialysate for peritoneal dialysis on the epithelial-tomesenchymal transition (EMT) of the mesothelial cell (MC) ex vivo [abstract]. NDT Plus 2010;3:iii477. [EMBASE: 7048471]
39. Fernandez-Perpen A, Perez-Lozano ML, Bajo MA, Albar-Vizcaino P, Sandovar Correa P, del Peso G, et al. Influence of bicarbonate/low-GDP peritoneal dialysis fluid (Bicavera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells. Peritoneal Dialysis International 2012;32 (3):292-304. [MEDLINE: 2221565]
40. Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. Journal of the American Society of Nephrology 2005;16(2):546-54. [MEDLINE: 1562507]
41. Fusshoeller A, Plail M, Ausobski G, Grabensee B, Plum J. Biocompatibility pattern of neutral bicarbonate/lactate buffered peritoneal dialysis solution in chronic APDpatients-a prospective; randomized; cross over study [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):214. [CENTRAL: CN-0078243]
42. Fusshoeller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrology Dialysis Transplantation 2004;19(8): 2101-6. [MEDLINE: 1521332]
43. Do J, Cho K, Park J, Yoon K, Cho D, Kim Y. Local and systemic effects of neutral pH, low GDP dialysate in CAPD patients [abstract no: SA-FC202]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):41A. [CENTRAL: CN-0044512]
44. Do J, Kim Y, Kim T, Park J, Yoon K, Park S. The effect of neutral pH, low GDPs dialysis solution on fluid, solute transport and edema control in CAPD patients [abstract no: SA-PO337]. Journal of American Society of Nephrology 2004;15(Oct):375A. [CENTRAL: CN-0058351]
45. Do JY, Kim YL, Park JW, Cho KH, Kim TW, Yoon KW, et al. The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients. Peritoneal Dialysis International 2005;25 Suppl 3:S22-5. [MEDLINE: 1604825]
46. Kim C, Kim Y, Park S, Do J, Yoon K, Lee E, et al. Effects of low glucose degradation products (GDPs) dialysis solution on the levels of surrogate markers of peritoneal inflammation, integrity and angiogenesis. Preliminary Report [abstract no: SA-PO822]. Journal of the American Society of Nephrology 2003;14(Nov):479A. [CENTRAL: CN-0058351]
47. Kim YL, Do J, Park SH, Cho K, Park J, Yoon K, et al. Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report. Nephrology 2003;8 Suppl:S28-32. [MEDLINE: 1501268]
48. Park J, Do J, Kim Y, Kim T, Yoon K, Park S. The effect of low GDPs solution on peritoneal fibrosis markers [abstract no: SA-PO333]. Journal of the American Society of Nephrology 2004;15(Oct):374A. [CENTRAL: CN-0058351]
49. Kim S, Kim SG, Oh JE, Chung W, Oh K, Kim YS, et al. Clinical benefits of a low glucose degradation products solution in patients starting peritoneal dialysis: preliminary report [abstract no: TH-PO809]. Journal of American Society of Nephrology 2006;17(Abstracts):278A. [CENTRAL: CN-0074054]
50. Kim S, Oh J, Kim SG, Chung W, Ahn C, Kim SG, et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrology Dialysis Transplantation 2009;24(9): 2899-908. [MEDLINE: 1925838]
51. Kim SG, Kim S, Hwang YH, Kim K, Oh JE, Chung W, et al. Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet study). Peritoneal Dialysis International 2008;28 Suppl 3:S117-22. [MEDLINE: 1855223]
52. Kim SJ, Oh JE, Chung WK, Oh KH, Kim SG. Effect of biocompatible PD fluid on preservation of residual renal function in incident CAPD patients: two-year extended follow-up study [abstract no: SA418]. NDT Plus 2010;3: iii175-iii176. [EMBASE: 7048388]
53. Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney International 2003; 63(4):1556-63. [MEDLINE: 1263137]
54. Konings CJ, Kooman JP, Schonck M, van der Sande FM, Hoorntje SJ, Leunissen KM. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters [abstract no: F-PO719]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts): 206a. [CENTRAL: CN-0044614]
55. Konings CJ, Schalkwijk CG, van der Sande FM, Leunissen KM, Kooman JP. Influence of icodextrin on plasma and dialysate levels of N-(carboxymethyl)lysine and N-(carboxyethyl)lysine. Peritoneal Dialysis International 2005; 25(6):591-5. [MEDLINE: 1641152]
56. Kooman JP, Schalkwijk CG, Konings CJ. The increase in plasma levels of N-(carboxymethyl)lysine during icodextrin treatment of peritoneal dialysis patients is not associated with increased plasma levels of vascular cell adhesion molecule-1. Peritoneal Dialysis International 2006;26(3): 410-1. [MEDLINE: 1672203]
57. Lai KN, Lam MF, Leung JC, Chan LY, Lam CW, Chan IH, et al. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. Peritoneal Dialysis International 2012;32(3): 280-91. [MEDLINE: 2204509]
58. Lin A, Qian J, Li X, Yu X, Liu W, Sun Y, et al. Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid. Clinical Journal of The American Society of Nephrology: CJASN 2009;4(11):1799-804. [MEDLINE: 1980822]
59. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney International 1998;53(4):1061-7. [MEDLINE: 955141]
60. Sprosen TS, Mactier RA, Gokal R, Lindbergh M, Tranaeus A, Faict D. Treatment of infusion pain (InP) with novel bicarbonate containing PD solutions [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):273A. [CENTRAL: CN-0044782]
61. Armstrong A, Sayers JA, Scrimgeour AC. Reduction in the prevalence of CAPD symptoms during 6 months treatment with icodextrin [abstract]. Nephrology Dialysis Transplantation 1996;11(6):A240. [CENTRAL: CN-0026130]
62. Gokal R, Mistry CD, Peers EM. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis. Peritoneal Dialysis International 1995;15(6):226-30. [MEDLINE: 757849]
63. Gokal R, Moberly J, Ogrinc F, Gordon A, Peers E, MIDAS Study Group. Improvement of hyperlipidemia with icodextrin use in CAPD patients [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):283A. [CENTRAL: CN-0044549]
64. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney International 1994; 46(2):496-503. [MEDLINE: 796736]
65. Pajek J, Kveder R, Bren A, Gucek A, Bucar M, Skoberne A, et al. Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study. Nephrology Dialysis Transplantation 2009;24(5):1617-25. [MEDLINE: 1906634]
66. Pajek J, Kveder R, Bren A, Gucek A, Ihan A, Osredkar J, et al. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Peritoneal Dialysis International 2008;28 (1):44-52. [MEDLINE: 1817894]
67. Pajek J, Kveder R, Gucek A, Skoberne A, Bren A, Bucar M, et al. Cell-free DNA in the peritoneal effluent of peritoneal dialysis solutions. Therapeutic Apheresis & Dialysis 2010;14 (1):20-6. [MEDLINE: 2043851]
68. Paniagua R, Orihuela O, Ventura MD, Avila-Diaz M, Cisneros A, Vicente-Martinez M, et al. Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis. Kidney International-Supplement 2008, (108): S125-30. [MEDLINE: 1837953]
69. Paniagua R, Ventura MD, Avila-Diaz M, Cisneros A, Vicente-Martinez M, Furlong MD, et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Peritoneal Dialysis International 2009;29(4):422-32. [MEDLINE: 1960260]
70. Plum J, Gentile S, Verger C, Brunkhorst R, Bahner U, Faller B, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. American Journal of Kidney Diseases 2002;39(4):862-71. [MEDLINE: 1192035]
71. Posthuma N, Verbrugh HA, Donker AJ, van Dorp W, Dekker HA, Peers EM, et al. Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years. Peritoneal Dialysis International 2000; 20(2):174-80. [MEDLINE: 1080924]
72. Posthuma N, ter Wee P, Donker AJ, Dekker HA, Oe PL, Verbrugh HA. Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients. Peritoneal Dialysis International 1999;19(4):334-42. [MEDLINE: 1050781]
73. Posthuma N, ter Wee PM. Icodextrin (I) use in CCPD patients during peritonitis: serum disaccharide levels and ultrafiltration (UF) [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A184. [CENTRAL: CN-0026143]
74. Posthuma N, ter Wee PM, Donker AJ, Dekker HAT, Oe PL, Verhoef J, et al. Ex vivo peritoneal defense characteristics and peritonitis rate in CCPD patients using glucose or icodextrin as daytime dwell [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):223A. [CENTRAL: CN-0044726]
75. Posthuma N, ter Wee PM, Donker AJ, Oe LP, Verbrugh HA, Peers E. Disaccharide ("total maltose") levels in CCPD patients using icodextrin [abstract]. Journal of the American Society of Nephrology 1995;6(3):513. [CENTRAL: CN-0048546]
76. Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh HA. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Peritoneal Dialysis International 2000;20 Suppl 2: S106-13. [MEDLINE: 1091165]
77. Posthuma N, ter Wee PM, Donker AJ, Oe PL, van Dorp W, Peers EM, et al. Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell. Peritoneal Dialysis International 1997;17(6):602-7. [MEDLINE: 965516]
78. Posthuma N, ter Wee PM, Donker AJ, Verbrugh HA, Oe PL, van Dorp W, et al. Icodextrin (I) use in CCPD patients during peritonitis: serum disaccharide (maltose) levels and ultrafiltration (UF) [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):270A. [CENTRAL: CN-0044726]
79. Posthuma N, ter Wee PM, Donker AJM, Oe LP, Verbrugh HA, Peers E. Improved ultrafiltration in CCPD patients using icodextrin (I) instead of glucose (G) for the long daytime dwell [abstract]. Journal of the American Society of Nephrology 1995;6(3):513. [CENTRAL: CN-0048546]
80. Posthuma N, ter Wee PM, Donker AJM, Verbrugh HA, Oe PL, van Dorp W. Peritoneal membrane characteristics in CCPD patients using glucose or icodextrin as daytime dwell [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):223A.
81. Posthuma N, ter Wee PM, Niessen H, Donker AJ, Verbrugh HA, Schalkwijk CG. Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin. Peritoneal Dialysis International 2001;21(1): 43-51. [MEDLINE: 1128049]
82. Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrology Dialysis Transplantation 1997;12(3):550-3. [MEDLINE: 907513]
83. Posthuma N, ter Weel PM, Donker AJ, Peers EM, Oe PL, Verbrugh HA. Icodextrin use in CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations. Nephrology Dialysis Transplantation 1998; 13(9):2341-4. [MEDLINE: 976151]
84. Rippe B, Christensson A, Haraldsson B, Simonsen O, Stelin G, Weiss L, et al. More Ca125 in dialysate after longterm treatment with a new, less toxic PD-fluid (PD-bio) [abstract]. Nephrology Dialysis Transplantation 1997;12(9): A180. [CENTRAL: CN-0050943]
85. Rippe B, Christensson A, Haraldsson B, Simonsen O, Stelin G, Weiss L, et al. Patient dialysate CA 125 and hyaluronan (HA) after 1, 6 and 12 months of treatment with a PDfluid containing less cytotoxic glucose degradation products [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):182A. [CENTRAL: CN-0044741]
86. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney International 2001;59(1):348-57. [MEDLINE: 1113509]
87. Rippe B, Wieslander A. Biologic significance of reduced levels of glucose degradation products. Peritoneal Dialysis International 2001;21 Suppl 3:S114-8. [MEDLINE: 1188780]
88. Rippe B, Wieslander A, Musi B. Long-term results with low glucose degradation product content in peritoneal dialysis fluids. Contributions to Nephrology 2003, (140):47-55. [MEDLINE: 1280034]
89. Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U, et al. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. Journal of the American Society of Nephrology 2003; 14(10):2632-8. [MEDLINE: 1451474]
90. Haas S, Schmitt CP, Schaefer F, Schaub T, Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS). Randomized cross-over evaluation of bicarbonate-vs lactate buffered PD solutions in children on APD [abstract]. Pediatric Nephrology 2002;17(Suppl):C53. [CENTRAL: CN-0044560]
91. Haas S, Schmitt CP, Schaub T, Schaefer F. Better biocompatibility and correction of acidosis using bicarbonate vs lactate buffered PDfluid in children on APD: a randomized cross-over clinical trial [abstract]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):202A. [CENTRAL: CN-0044561]
92. Schmitt C, Haas S, Schaub T, Schaefer F. Randomized crossover administration of pH-neutral, bicarbonate buffered PD solution in children on APD [abstract no: O51]. Nephrology Dialysis Transplantation 2002;17(Suppl 12):17.
93. Schmitt CP, Doetschmann R, Kirchgessner J, Mehls O, Schaefer F. Comparison of solute and acid-base transport kinetics in children using bicarbonate-vs. lactatebuffered PD solutions [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):193A. [CENTRAL: CN-0044763]
94. Schmitt CP, Haraldsson B, Doetschmann R, Zimmering M, Greiner C, Boswald M, et al. Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children. Kidney International 2002;61(4): 1527-36. [MEDLINE: 1191876]
95. Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, et al. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrology Dialysis Transplantation 2007;22(7):2038-44. [MEDLINE: 1742016]
96. Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucosedegradation products-a 1-year randomized control trial. Nephrology Dialysis Transplantation 2007;22(2):552-9. [MEDLINE: 1700552]
97. Takatori Y, Akagi S, Sugiyama H, Inoue J, Kojo S, Morinaga H, et al. Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial. Clinical Journal of The American Society of Nephrology: CJASN 2011;6(6):1337-44. [MEDLINE: 2149374]
98. Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N, Bicarbonate/Lactate Study Group. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Peritoneal Dialysis International 2001;21 Suppl 3:S102-7. [MEDLINE: 1188780]
99. Holmes CJ, Jones S, Mackenzie R, Coles GA, Williams JD, Tranaeus A, et al. Bicarbonate/lactate-buffered (TBL) peritoneal dialysis fluid (PDF) decreases pro-collagen I levels in peritoneal dialysis effluent (PDE) [abstract no: A1214]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):264A. [CENTRAL: CN-0044576]
100. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney International 2001;59(4): 1529-38. [MEDLINE: 1126041]
101. Jones S, Holmes CJ, Mackenzie RK, Stead R, Coles GA, Williams JD, et al. Continuous dialysis with bicarbonate/lactate-buffered peritoneal dialysis fluids results in a longterm improvement in ex vivo peritoneal macrophage function. Journal of the American Society of Nephrology 2002; 13 Suppl 1:S97-103. [1179276]
102. Topley N, Jones S, Holmes CJ, Mackenzie R, Coles GA, Faict D, et al. In vivo exposure to bicarbonate/lactatebuffered (TBL) peritoneal dialysis fluid (PDF) decreases pro-collagen I and TGF-b1 (TGF-b1) levels in peritoneal dialysis effluent (PDE) [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):290A. [CENTRAL: CN-0044803]
103. Topley N, Krediet R, Jones S, Faict D, Tranaeus A, Holmes C. Peritoneal dialysate CA125, hyaluronan (HA), TGFb1 and pro-collagen I peptide (PICP) in a randomized, controlled study of bicarbonate/lactate based CAPD solution. [abstract no: A1169]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):230A. [CENTRAL: CN-0058376]
104. Tranaeus A. A long-term study of a bicarbonate/lactatebased peritoneal dialysis solution-clinical benefits. The Bicarbonate/Lactate Study Group. Peritoneal Dialysis International 2000;20(5):516-23. [MEDLINE: 1111724]
105. Weiss L, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert CE, et al. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Peritoneal Dialysis International 2009;29(6):647-55. [MEDLINE: 1991056]
106. Guo A, Just P. Quality of life of peritoneal dialysis patients on icodextrin: a longitudinal study [abstract]. Quality of Life Research 2002;11(7):667. [CENTRAL: CN-0049377]
107. Guo A, Wolfson M, Holt R. Early quality of life benefits of icodextrin in peritoneal dialysis. Kidney International-Supplement 2002, (81):S72-9. [MEDLINE: 1223048]
108. Wolfson M, Hagen T, Ogrinc F, Martis L, Icodextrin Study G. One year results-icodextrin vs dextrose for the long dwell in peritoneal dialysis [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):317A.
109. Wolfson M, Hagen T, Ogrinc F, Martis L, Icodextrin Study Group. Effects of icodextrin on ultrafiltration (UF) and small solute clearance in continuous ambulatory dialysis patients (CAPD) [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):317A. [CENTRAL: CN-0065381]
110. Wolfson M, Piraino B, Hamburger RJ, Morton AR, Icodextrin Study Group. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. American Journal of Kidney Diseases 2002;40(5): 1055-65. [MEDLINE: 1240765]
111. Zeier M, Deppisch R, Haug U, Schwenger V, Henle T, Bahner U, et al. Resorption of age-promoting glucose degradation products (GDP) from peritoneal dialysis (PD) fluids leads to increased levels of age in plasma [abstract]. Journal of the American Society of Nephrology 2000;11(Sept): 223A. [CENTRAL: CN-0058387]
112. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?. Kidney International 2003;63(1): 298-305. [MEDLINE: 12472796]